SecSonar.com

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Aclaris Therapeutics, Inc. (ACRS) is a Biotechnology company based in US with a market capitalization of $546.3M. Revenue declined 58.2% year-over-year and free cash flow was negative at -$47.2M. This page tracks ACRS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 61 employees · IPO Oct 6, 2015

Valuation

Valuation & price

$4.80 · as of May 15, 2026 · -13.7% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.30

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$5.56$3.51$1.46Jul 25Dec 25Jul 26Jul 7, 25$1.46Jul 9, 25$1.54Jul 11, 25$1.57Jul 15, 25$1.52Jul 17, 25$1.59Jul 21, 25$1.64Jul 23, 25$1.68Jul 25, 25$1.70Jul 29, 25$1.55Jul 31, 25$1.53Aug 4, 25$1.56Aug 6, 25$1.55Aug 11, 25$1.64Aug 13, 25$1.70Aug 15, 25$1.87Aug 19, 25$1.79Aug 21, 25$1.75Aug 25, 25$1.80Aug 27, 25$1.82Aug 29, 25$1.93Sep 3, 25$2.06Sep 5, 25$2.10Sep 9, 25$2.13Sep 11, 25$1.97Sep 16, 25$1.84Sep 18, 25$1.95Sep 22, 25$1.93Sep 24, 25$1.87Sep 26, 25$1.99Sep 30, 25$1.90Oct 2, 25$1.84Oct 6, 25$1.90Oct 8, 25$1.90Oct 10, 25$1.87Oct 14, 25$1.81Oct 16, 25$2.05Oct 21, 25$2.38Oct 23, 25$2.26Oct 27, 25$2.34Oct 29, 25$2.34Oct 31, 25$2.52Nov 4, 25$2.36Nov 6, 25$2.27Nov 10, 25$2.13Nov 12, 25$2.41Nov 14, 25$2.52Nov 18, 25$2.49Nov 20, 25$2.41Nov 25, 25$2.73Nov 28, 25$2.83Dec 2, 25$2.70Dec 4, 25$3.01Dec 8, 25$3.28Dec 10, 25$3.27Dec 12, 25$3.25Dec 16, 25$3.21Dec 18, 25$3.08Dec 22, 25$3.07Dec 24, 25$3.04Dec 29, 25$3.01Jan 2, 26$2.88Jan 6, 26$2.65Jan 8, 26$2.68Jan 12, 26$2.66Jan 14, 26$2.74Jan 16, 26$2.62Jan 21, 26$4.42Jan 23, 26$4.50Jan 27, 26$3.87Jan 29, 26$3.43Feb 2, 26$3.61Feb 4, 26$3.54Feb 9, 26$3.69Feb 11, 26$3.39Feb 13, 26$3.19Feb 18, 26$3.17Feb 20, 26$3.24Feb 24, 26$3.36Feb 26, 26$3.13Mar 2, 26$3.05Mar 4, 26$3.10Mar 6, 26$3.06Mar 10, 26$3.67Mar 12, 26$3.51Mar 17, 26$3.88Mar 19, 26$3.74Mar 23, 26$3.58Mar 25, 26$3.59Mar 27, 26$3.52Mar 31, 26$3.75Apr 2, 26$4.20Apr 7, 26$3.75Apr 9, 26$4.08Apr 13, 26$3.90Apr 15, 26$3.93Apr 17, 26$4.25Apr 22, 26$4.39Apr 24, 26$4.30Apr 28, 26$4.22Apr 30, 26$4.34May 4, 26$4.53May 6, 26$4.78May 8, 26$4.93May 12, 26$4.88May 14, 26$4.80May 18, 26$4.40May 20, 26$4.53May 22, 26$4.52May 28, 26$4.57Jun 1, 26$4.34Jun 3, 26$4.42Jun 5, 26$4.36Jun 9, 26$4.30Jun 11, 26$4.37Jun 15, 26$4.36Jun 17, 26$4.42Jun 22, 26$4.84Jun 24, 26$4.79Jun 26, 26$5.00Jul 2, 26$5.56
$1.4552-week range$5.56
Loading valuation history…

Fundamentals

Key fundamentals

$546.3M

Market cap

-58.2%

Revenue growth (YoY)

73.3%

Gross margin

-$47.2M

Free cash flow (USD)

-$88.6M

Net debt

Net cash position

58.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$1.7MFY 2018$10.1MFY 2019$4.2MFY 2020$6.5MFY 2021$6.8MFY 2022$29.8MFY 2023$31.2MFY 2024$18.7MFY 2025$7.8M
$0$7.8M

Free cash flow by year

2016 → 2025

FY 2016$-34.8MFY 2017$-55.9MFY 2018$-102.2MFY 2019$-98.1MFY 2020$-39.1MFY 2021$-52.4MFY 2022$-68.2MFY 2023$-79.6MFY 2024$-20.2MFY 2025$-47.2M
-$34.8M-$47.2M

Gross margin by year

2021 → 2025

FY 202130.3%FY 202259.8%FY 202342.1%FY 202485.1%FY 202573.3%
30.3%73.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 4, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventClinical Pipeline UpdateApr 28, 2026Filing
  • Insider sellInsider Sell $1.4MLeonard Braden Michael · 10% Owner · $1.4MApr 27, 2026Filing

Questions

Frequently asked questions

What is Aclaris Therapeutics, Inc.'s market cap?

Aclaris Therapeutics, Inc. (ACRS) has a market capitalization of $546.3M.

What is ACRS's P/E ratio?

A meaningful P/E ratio is not available for ACRS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ACRS's price-to-book (P/B) ratio?

ACRS trades at 5.30 times book value per share.

Are insiders buying ACRS stock?

SEC Form 4 filings show no open-market insider buys at Aclaris Therapeutics, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

MDXG

MiMedx Group, Inc.

$553.3M

RIGL

Rigel Pharmaceuticals, Inc.

$562.1M

VALN

Valneva SE

$563.3M

PRTA

Prothena Corporation plc

$528.8M

ALLO

Allogene Therapeutics, Inc.

$524.6M

XOMA

XOMA Royalty Corp.

$523.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.